Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$17.5 million.

  • Heron Therapeutics' Profit After Tax fell 26087.05% to -$17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.6 million, marking a year-over-year increase of 5144.99%. This contributed to the annual value of -$13.6 million for FY2024, which is 8771.7% up from last year.
  • Heron Therapeutics' Profit After Tax amounted to -$17.5 million in Q3 2025, which was down 26087.05% from -$2.4 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Profit After Tax registered a high of $3.7 million during Q4 2024, and its lowest value of -$63.9 million during Q1 2022.
  • Moreover, its 5-year median value for Profit After Tax was -$25.0 million (2023), whereas its average is -$28.6 million.
  • The largest annual percentage gain for Heron Therapeutics' Profit After Tax in the last 5 years was 18338.61% (2025), contrasted with its biggest fall of 26087.05% (2025).
  • Over the past 5 years, Heron Therapeutics' Profit After Tax (Quarter) stood at -$54.6 million in 2021, then skyrocketed by 63.64% to -$19.9 million in 2022, then surged by 46.03% to -$10.7 million in 2023, then skyrocketed by 134.16% to $3.7 million in 2024, then tumbled by 577.61% to -$17.5 million in 2025.
  • Its last three reported values are -$17.5 million in Q3 2025, -$2.4 million for Q2 2025, and $2.6 million during Q1 2025.